Fourier Intelligence Inks Strategic Alliance Partnership with MyndTec Inc.
Fourier Intelligence Inks Strategic Alliance Partnership with MyndTec Inc.
The award-winning Canadian MyndMove(TM) therapy from MyndTec. Inc joins SoftBank-backed rehab robotics leader, Fourier Intelligence's network of partners
來自 myndTec 的屢獲殊榮的加拿大 myndMove (TM) 療法。Inc. 加入軟銀支持的康復機器人領導者傅立葉情報的合作伙伴網絡
Singapore, Singapore--(Newsfile Corp. - March 22, 2022) - Fourier Intelligence has announced a strategic alliance partnership with MyndTec Inc., an award-winning Canadian medical technology company specialising in innovative therapeutic medical devices.
新加坡,新加坡--(Newsfile Corp.,2022年3月22日)——傅立葉智能宣佈與屢獲殊榮的加拿大醫療技術公司MyndTec Inc. 建立戰略聯盟合作伙伴關係,專門從事創新的治療性醫療器械。
This partnership will focus on the distribution of MyndMove™, a non-invasive functional electrical stimulation-based intervention, to the ever-expanding global network of Fourier Intelligence.
該合作伙伴關係將側重於向不斷擴大的傅立葉智能全球網絡分發myndMove™(一種基於功能性電刺激的非侵入性干預措施)。
A virtual signing ceremony was held to commemorate the partnership between both parties. MyndTec's CEO, Craig Leon, Co-Founder, Dr Milos R. Popovic, Fourier Intelligence Co-Founder and Global HQ CEO, Zen Koh, General Manager, Owen Teoh and Operations Director, Sandra Lee, attended the virtual event.
舉行了虛擬簽字儀式,以紀念雙方之間的夥伴關係。MyndTec首席執行官克雷格·萊昂、聯合創始人克雷格·萊昂、傅立葉情報聯合創始人兼全球總部首席執行官Milos R. Popovic博士、總經理Owen Teoh和運營董事桑德拉·李出席了虛擬活動。
This partnership is timely as both parties recently reached strategic milestones. Fourier Intelligence received a Series D growth investment led by the SoftBank Group and backed by the Saudi Aramco P7 Venture Fund and the Yuanjing Capital earlier this year. MyndTec met all the requirements of the Canadian Securities Exchange (CSE) and began trading its common shares on the CSE on February 24th under the ticker symbol MYTC.
這種夥伴關係是及時的,因爲雙方最近達到了戰略里程碑。今年早些時候,傅立葉情報獲得了由軟銀集團牽頭、沙特阿美P7風險基金和元景資本支持的D輪增長投資。MyndTec符合加拿大證券交易所(CSE)的所有要求,並於2月24日開始在CSE交易其普通股第四 在股票代碼 MYTC 下。
"Our partnership with MyndTec Inc. signifies yet another successful strategic collaboration with market leaders to offer innovative and clinically effective technology for our patients globally," said Zen Koh, Co-Founder and Global HQ CEO of Fourier Intelligence. "MyndMove™, an electrical stimulation-based intervention, integrates perfectly into Fourier's RehabHub™ solution and complement our existing product/technology portfolio. Fourier will continue our investment into more of such joint technological developments to better provide highly integrated intelligent rehabilitation technologies to empower clinicians and patients."
傅立葉智能聯合創始人兼全球總部首席執行官Zen Koh表示:“我們與MyndTec Inc.的合作標誌着我們與市場領導者的又一次成功的戰略合作,爲我們的全球患者提供創新和臨床有效的技術。”“myndMove™ 是一種基於電刺激的干預措施,它完美地集成到傅立葉的RehabHub™ 解決方案中,並補充了我們現有的產品/技術組合。傅立葉將繼續投資於更多此類聯合技術開發,以更好地提供高度集成的智能康復技術,增強臨床醫生和患者的能力。”
Fourier's global network spans over 50 countries to ensure a broad market outreach for innovative technologies. With joint laboratories with some of the top research institutes in the world such as ETH Zürich, University of Melbourne, and Shirley Ryan AbilityLab in Chicago, Fourier is set to chart the new frontier of innovative medical technologies.
傅立葉的全球網絡橫跨50多個國家,以確保創新技術的廣泛市場覆蓋。傅立葉與蘇黎世聯邦理工學院、墨爾本大學和芝加哥的Shirley Ryan AbilityLab等世界頂級研究機構建立了聯合實驗室,將開闢創新醫療技術的新前沿。
"We are excited to enter into this meaningful partnership with Fourier Intelligence to strategically integrate our MyndMove™ technology into RehabHub™. Fourier's proven track record establishing globally successful RehabHub™, positively changing patient lives globally and the addition of MyndTec's innovative MyndMove™ therapy to this network will enable us to reach out to more patients worldwide," said Craig Leon, CEO of MyndTec.
“我們很高興能與傅立葉智能建立這種有意義的合作伙伴關係,將我們的myndMove™ 技術戰略性地整合到RehabHub™ 中。傅立葉在建立全球成功的RehabHub™、積極改變全球患者的生活以及在該網絡中加入MyndTec的創新MyndMove™ 療法將使我們能夠接觸到全球更多的患者,” myndTec首席執行官克雷格·萊昂說。
MyndTec's medical devices are designed to improve function, maximise independence, and enhance the quality of life for individuals with upper limb paralysis due to stroke, spinal cord injury, or some cases of traumatic brain injury.*
MyndTec 的醫療設備旨在改善因中風、脊髓損傷或某些創傷性腦損傷而導致上肢癱瘓的人的功能、最大限度地提高獨立性並提高生活質量。*
MyndTec Inc. also partners with several organisations such as the KITE Research Institute, the research arm of the Toronto Rehabilitation Institute - University Health Network and the University of Toronto to develop and commercialise MyndMove™ therapy. The MyndMove™ therapy is also supported by numerous clinical studies, including randomised controlled trials in stroke and spinal cord injuries. The embedded stimulation protocols in MyndMove™ allows clinicians to stimulate natural, purposeful, and functional movements in patients.
MyndTec Inc. 還與多倫多康復研究所-大學健康網絡的研究機構KITE研究所和多倫多大學等多個組織合作,開發和商業化myndMove™ 療法。MyndMove™ 療法還得到了許多臨床研究的支持,包括中風和脊髓損傷的隨機對照試驗。MyndMove™ 中的嵌入式刺激方案允許臨床醫生刺激患者自然、有目的和功能性的運動。
*Disclaimer: MyndMove claims may differ depending on jurisdiction. Please contact MyndTec for details.
*免責聲明:myndMove 索賠可能因司法管轄區而異。請聯繫 myndTec 瞭解詳情。
Media Contact
媒體聯繫人
Fourier Intelligence
Grace NG
Senior Marketing Manager
Email: marketing.globalhq@fftai.com
傅立葉智能
格蕾絲 NG
高級營銷經理
電子郵件:marketing.globalhq@fftai.com
MyndTec Inc.
Craig Leon
Email: investor.relations@myndtec.com
(416) 569-0430
myndTec Inc.
克雷格萊昂
電子郵件:investor.relations@myndtec.com
(416) 569-0430
About MyndTec
關於 myndTec
Co-founded in 2008 by Dr. Milos Popovic, MyndTec is a Canadian medical technology company dedicated to the development and commercialization of innovative products that improve function, maximize independence and enhance the quality of life for individuals who have suffered injury to the central nervous system as a result of stroke, spinal cord injury and certain traumatic brain injuries. The Company develops non-invasive neurological and nervous system electrical stimulation therapeutics for the treatment of neurological diseases and injury specifically targeted to markets with large, growing and global patient populations. The Company's flagship product MyndMove™ is a non-invasive functional electrical stimulation-based intervention. MyndMove™ uses neuroplasticity mechanisms to stimulate development of new neural efferent and afferent pathways allowing patients to re-establish voluntary movement and improve independence in their activities of daily living. The MyndMove™ system offers trained therapists the ability to assist individuals affected with paralysis to improve voluntary control of their limbs. The MyndMove™ therapy system offers a broad spectrum of sophisticated functional electrical stimulation software protocols which therapists customize to patient needs to enable meaningful controlled movements via proprietary stimulation technology.
MyndTec由Milos Popovic博士於2008年共同創立,是一家加拿大醫療技術公司,致力於開發和商業化創新產品,這些產品可改善因中風、脊髓損傷和某些創傷性腦損傷而中樞神經系統受傷的人的功能、最大限度地提高獨立性和生活質量。該公司開發用於治療神經系統疾病和損傷的非侵入性神經系統和神經系統電刺激療法,專門針對全球患者羣體龐大、不斷增長的市場。該公司的旗艦產品myndMove™ 是一種基於功能性電刺激的非侵入性干預措施。myndMove™ 使用神經可塑性機制來刺激新的神經傳出和傳入途徑的發育,使患者能夠重新建立自願運動,提高日常生活活動的獨立性。MyndMove™ 系統使訓練有素的治療師能夠幫助癱瘓患者改善對四肢的自願控制。myndMove™ 治療系統提供各種複雜的功能性電刺激軟件方案,治療師可根據患者的需求進行定製,通過專有的刺激技術實現有意義的受控運動。
Cautionary Note Regarding Forward-Looking Statements
關於前瞻性陳述的警示說明
This news release contains forward-looking statements that constitute "forward-looking information" within the meaning of applicable Canadian securities laws (collectively, "forward-looking statements"). All statements in this news release that are not historical facts are forward-looking statements, including, but not limited to, all statements regarding: events, performance or results of operations that the Company believes, expects or anticipates will or may occur in the future; and its strategic re-launch of MyndMove devices in the United States. Forward-looking statements are typically, but not always, identified by words such as: "believes", "expects", "aim", "anticipates", "intends", "estimates", "plans", "may", "should", "could", "continue", "would", "will", "potential", "scheduled", "goal", "target", or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved.
本新聞稿包含前瞻性陳述,這些陳述構成適用的加拿大證券法所指的 “前瞻性信息”(統稱爲 “前瞻性陳述”)。本新聞稿中所有非歷史事實的陳述均爲前瞻性陳述,包括但不限於有關以下內容的所有陳述:公司認爲、預期或預計未來將或可能發生的事件、業績或經營業績;以及其在美國戰略性地重新推出MyndMove設備。前瞻性陳述通常但並非總是用諸如 “相信”、“期望”、“目標”、“預期”、“打算”、“估計”、“計劃”、“可能”、“繼續”、“將”、“將”、“將”、“潛在”、“預定”、“目標”、“目標” 或此類詞語和短語的變體以及類似表達方式的變體等詞語來識別, 就其性質而言, 它們是指未來可能發生的事件或結果, 可能發生, 可能發生或將要發生或取得或實現.
Forward-looking statements are necessarily based on a number of estimates and assumptions that include, but are not limited to: expected future development; general economic conditions; the ability of the Company to execute on its business objectives; and other estimates and assumptions described in the Company's Listing Statement dated February 18, 2022 (the "Listing Statement"), a copy of which is available under the Company's profile on SEDAR at . Forward-looking statements are inherently subject to a number of significant risks and uncertainties that could cause the actual results or events to differ materially from those described in the forward-looking statements. Important risks and uncertainties that could cause actual results or events to differ materially from expectations include, but are not limited to: the Company's ability to continue as a going concern, the Company's research, development and commercialization of its products could be stopped or delayed if any third party fails to provide sufficient quantities of products or components, or fails to do so at acceptable quality levels or prices, or fails to maintain or achieve satisfactory regulatory compliance; the Company expects to incur significant ongoing costs and obligations relating to its investment in infrastructure, growth, research and development, regulatory compliance and operations; and other risks and uncertainties described in the Listing Statement. The Company has attempted to identify important factors that could cause actual results, performance or achievements to vary from those expectations expressed or implied by the forward-looking statements, however, there may be other factors that cause results, performance or achievements not to be as expected and that could cause actual results, performance or achievements to differ materially from current expectations. These forward-looking statements are only current as of the date of this news release. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties and the Company provides no assurance that they will prove to be correct. Readers should not place undue reliance on such forward-looking statements. The Company does not undertake any obligation to update forward-looking statements contained herein, other than as required by applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
前瞻性陳述必須基於許多估計和假設,包括但不限於:預期的未來發展;總體經濟狀況;公司執行其業務目標的能力;以及公司2022年2月18日上市聲明中描述的其他估計和假設( “上市聲明”),其副本可在SEDAR的公司簡介下查閱,網址爲。前瞻性陳述本質上存在許多重大風險和不確定性,這些風險和不確定性可能導致實際結果或事件與前瞻性陳述中描述的結果或事件存在重大差異。可能導致實際業績或事件與預期存在重大差異的重要風險和不確定性包括但不限於:如果任何第三方未能提供足夠數量的產品或組件,或者未能在可接受的質量水平或價格下提供,或者未能保持或實現令人滿意的監管合規性,公司繼續作爲持續經營企業的能力,公司對其產品的研究、開發和商業化可能會停止或推遲;公司預計將產生大量持續的監管合規性;公司預計將產生大量持續的監管合規性成本以及與其基礎設施投資、增長、研發、監管合規和運營相關的義務;以及上市聲明中描述的其他風險和不確定性。公司試圖確定可能導致實際業績、業績或成就與前瞻性陳述所表達或暗示的預期有所不同的重要因素,但是,可能還有其他因素會導致業績、業績或成就不如預期,並可能導致實際業績、業績或成就與當前預期存在重大差異。這些前瞻性陳述僅爲截至本新聞稿發佈之日的最新陳述。儘管公司認爲此類前瞻性陳述中反映的預期是合理的,但此類陳述涉及風險和不確定性,公司不保證這些陳述會被證明是正確的。讀者不應過分依賴此類前瞻性陳述。除適用法律要求外,公司不承擔任何更新此處包含的前瞻性陳述的義務。所有前瞻性陳述均受本警示性聲明的全部限制。
The CSE has in no way passed upon the merits of the business of the Company and has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.
CSE絲毫沒有透露公司業務的優點,既沒有批准也沒有不批准本新聞稿的內容,對本新聞稿的充分性或準確性不承擔任何責任。
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
不適用於分發給美國新聞通訊社或在美國傳播
To view the source version of this press release, please visit
要查看本新聞稿的源版本,請訪問